PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
52.82%
R&D growth above 1.5x AGEN's 17.37%. Michael Burry would check for spending discipline.
-14.04%
Both companies reducing G&A. Martin Whitman would check industry cost trends.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
9.04%
Operating expenses growth while AGEN reduces costs. John Neff would investigate differences.
9.04%
Total costs growth while AGEN reduces costs. John Neff would investigate differences.
104.89%
Interest expense growth while AGEN reduces costs. John Neff would investigate differences.
No Data
No Data available this quarter, please select a different quarter.
-9.04%
EBITDA decline while AGEN shows 6.77% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-9.04%
Operating income decline while AGEN shows 7.01% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
114.37%
Other expenses growth 1.25-1.5x AGEN's 86.79%. Martin Whitman would scrutinize cost items.
48.96%
Pre-tax income growth 1.25-1.5x AGEN's 34.31%. Bruce Berkowitz would examine sustainability.
No Data
No Data available this quarter, please select a different quarter.
135.99%
Tax expense growth above 1.5x AGEN's 17.47%. Michael Burry would check for concerning trends.
48.96%
Net income growth 1.25-1.5x AGEN's 34.31%. Bruce Berkowitz would examine sustainability.
No Data
No Data available this quarter, please select a different quarter.
53.59%
EPS growth 1.25-1.5x AGEN's 39.75%. Bruce Berkowitz would examine sustainability.
51.99%
Diluted EPS growth 1.25-1.5x AGEN's 39.75%. Bruce Berkowitz would examine sustainability.
10.21%
Share count reduction below 50% of AGEN's 8.98%. Michael Burry would check for concerns.
6.42%
Diluted share reduction below 50% of AGEN's 8.98%. Michael Burry would check for concerns.